BIOMARIN PHARMACEUTICAL INC (BMRN) Form 8-K — Oct 6, 2026

$BMRNForm 8-KItems 2.02Filed Oct 6, 2026, 4:22 PM ET0001048477-26-000019Original filing

BioMarin disclosed via 8-K that its Q3 2026 results will include approximately $283 million in pre-tax acquired IPR&D charges from the Alesta Therapeutics acquisition completed August 31, 2026. This represents an unfavorable impact of roughly $1.50 to both GAAP and Non-GAAP Diluted EPS for the quarter.

Key figures

Fy2026 eps impact: -$1.55 (GAAP and Non-GAAP diluted)
Q3 2026 eps impact: -$1.50 (GAAP and Non-GAAP diluted)
Q3 2026 iprd charge pretax: $283 million
Fy2026 total pretax charges: $320 million

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.